Gelatin-Gallic Acid Microcomplexes Release GO/Cu Nanomaterials to Eradicate Antibiotic-Resistant Microbes and Their Biofilm.

Wound-infecting bacteria are typically Pseudomonas aeruginosa and Staphylococcus epidermidis, both of which form biofilms and become resistant to antibiotics. To solve this problem, copper nanoparticles (Cu) on graphene oxide (GO) nanosheets were used as antibacterial materials. Since the excessive use of antibacterial substances is fatal to normal tissues, GO/Cu was encapsulated with a gelatin complex to lower the cytotoxicity. Among the catechol-based substances, gallic acid (GA), which has anti-inflammatory and antibacterial properties, was used in this study to impart stability to the gelatin complex. Gelatin (GE) and gallic acid (GA) were combined by a crosslinking method using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/N-hydroxysuccinimide (NHS) as a crosslinker, and the crosslinking was confirmed by Fourier transform infrared (FT-IR), 1H NMR, and the fluorescence property of GA. The GO/Cu@GE-GA microcomplexes exhibited more antibacterial effect against Gram-positive bacteria (S. epidermidis) and Gram-negative bacteria (P. aeruginosa) than when GO/Cu alone was used, and the antibiofilm effect was also confirmed. The cytotoxicity evaluation for human skin cells (human dermal fibroblast (HDF)) at the same concentration showed that it had low cytotoxicity and biocompatibility. This study shows the potential of antimicrobial gelatin microcomplex in prohibiting infectious bacteria and their biofilms and controlling the release of antimicrobial substances.

Physiological significance of elevated levels of lactate by exercise training in the brain and body.

For the past 200 years, lactate has been regarded as a metabolic waste end product that causes fatigue during exercise. However, lactate production is closely correlated with energy metabolism. The lactate dehydrogenase-catalyzed reaction uses protons to produce lactate, which delays ongoing metabolic acidosis. Of note, lactate production differs depending on exercise intensity and is not limited to muscles. Importantly, controlling physiological effect of lactate may be a solution to alleviating some chronic diseases. Released through exercise, lactate is an important biomarker for fat oxidation in skeletal muscles. During recovery after sustained strenuous exercise, most of the lactate accumulated during exercise is removed by direct oxidation. However, as the muscle respiration rate decreases, lactate becomes a desirable substrate for hepatic glucose synthesis. Furthermore, improvement in brain function by lactate, particularly, through the expression of vascular endothelial growth factor and brain-derived neurotrophic factor, is being increasingly studied. In addition, it is possible to improve stress-related symptoms, such as depression, by regulating the function of hippocampal mitochondria, and with an increasingly aging society, lactate is being investigated as a preventive agent for brain diseases such as Alzheimer's disease. Therefore, the perception that lactate is equivalent to fatigue should no longer exist. This review focuses on the new perception of lactate and how lactate acts extensively in the skeletal muscles, heart, brain, kidney, and liver. Additionally, lactate is now used to confirm exercise performance and should be further studied to assess its impact on exercise training.

Surface glycan targeting for cancer nano-immunotherapy.

Cancer immunotherapy is an emerging therapeutic strategy for cancer treatment. Most of the immunotherapeutics approved by the FDA regulate the innate immune system and associated immune cell activity, with immune check inhibitors in particular having transformed the field of cancer immunotherapy due to their significant clinical potential. However, previously reported immunotherapeutics have exhibited undesirable side effects, including autoimmune toxicity and inflammation. Controlling these deleterious responses and designing therapeutics that can precisely target specific regions are thus crucial to improving the efficacy of cancer immunotherapies. Recent studies have reported that cancer cells employ glycan-immune checkpoint interactions to modulate immune cell activity. Thus, the recognition of cancer glycan moieties such as sialoglycans may improve the anticancer activity of immune cells. In this review, we discuss recent advances in cancer immunotherapies involving glycans and glycan-targeting technologies based on nanomaterial-assisted local delivery systems.